Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

BACKGROUND: CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated with considerable toxicity, providing the ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Luke, Jason J, Barlesi, Fabrice, Chung, Ki, Tolcher, Anthony W, Kelly, Karen, Hollebecque, Antoine, Le Tourneau, Christophe, Subbiah, Vivek, Tsai, Frank, Kao, Steven, Cassier, Philippe A, Khasraw, Mustafa, Kindler, Hedy L, Fang, Hua, Fan, Frances, Allaire, Kathryn, Patel, Maulik, Ye, Shiming, Chao, Debra T, Henner, William R, Hayflick, Joel S, McDevitt, Michael A, Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898862/
https://www.ncbi.nlm.nih.gov/pubmed/33608377
http://dx.doi.org/10.1136/jitc-2020-002015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898862/
https://www.ncbi.nlm.nih.gov/pubmed/33608377
http://dx.doi.org/10.1136/jitc-2020-002015

Ejemplares similares